Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 7/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | TSPO | P30536 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21733765 | 1.00 | HCRTR1 (0.33) | HCRTR1HCRTR2CNR1CNR2TSPO | |
| SCHEMBL21733823 | 0.90 | HCRTR1 (0.32) | HCRTR1HCRTR2CNR1CNR2 | |
| SCHEMBL21733487 | 0.89 | NR3C1 (0.34) | HCRTR1HCRTR2CNR1CNR2TSPO | |
| SCHEMBL21733489 | 0.87 | TSPO (0.31) | HCRTR1HCRTR2CNR1CNR2TSPO | |
| SCHEMBL21733790 | 0.84 | MEN1 (0.35) | HCRTR1HCRTR2CNR1CNR2ALDH1A1 | |
| SCHEMBL28493072 | 0.82 | TSPO (0.32) | TSPONR3C1ALDH1A1 | |
| SCHEMBL21733808 | 0.81 | TSPO (0.35) | HCRTR1HCRTR2CNR1CNR2TSPO | |
| SCHEMBL21733848 | 0.81 | CNR1 (0.32) | HCRTR1HCRTR2CNR1CNR2NR3C1 | |
| SCHEMBL21733785 | 0.80 | KMT2A (0.32) | CNR1CNR2ALDH1A1 | |
| SCHEMBL21733838 | 0.80 | TP53 (0.32) | HCRTR2TSPOALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2020035031-A1 | FUSED RING COMPOUNDS | GENENTECH, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | HCRTR1 4575/4885HCRTR2 4007/4885CNR1 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.